Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2022

Efficacité et innocuité du risankizumab dans le traitement du rhumatisme psoriasique actif : résultats à 52 semaines de l'étude KEEPsAKE 1

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac607

Kristensen LE,

Keiserman M,

Papp K,

McCasland L,

White D,

Lu W,

Risankizumab (RZB) improves the signs and symptoms of PsA, with efficacy maintained through 52 weeks. Alongside the efficacy data, this analysis of KEEPsAKE 1 also evaluates the safety and tolerability profile of RZB.

Keywords:

August 2022

Le risankizumab améliore la qualité de vie liée à la santé, la fatigue, la douleur et la productivité au travail dans le rhumatisme psoriasique : résultats de l'étude KEEPsAKE 1

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac342

Kristensen LE,

Soliman AM,

Papp K,

White D,

Barcomb L,

Lu W,

Eldred A,

Behrens F.

In this study risankizumab treatment resulted in greater improvements in fatigue and pain than placebo. Prior to this finding the study aimed to evaluate the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial.

Keywords:

Efficacité et sécurité du sécukinumab chez les patients atteints de spondylarthrite et d'enthésite du tendon d'Achille : résultats d'un essai de phase 3b

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab784

Patel Y,

Baraliakos X; ACHILLES study group

Secukinumab improves the burden of heel enthesitis as assessed by patient and physician reported outcomes in patients with active SpA refractory to standard treatment. In coming to this conclusion, the ACHILLES trial aimed to demonstrate the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients.

Keywords:

June 2022

Efficacité et innocuité du Deucravacitinib, un inhibiteur sélectif de TYK2, dans un essai de phase II dans le rhumatisme psoriasique

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2021-221664

Neal J,

Kim J,

Singhal S,

Nowak M,

Banerjee S

In this study Mease, et al. aimed to evaluate the efficacy and safety of deucravacitinib in patients with active PsA. Treatment with the selective TYK2i deucravacitinib was well tolerated and resulted in greater improvements than placebo in ACR-20 as well as Multiplicity-controlled secondary endpoints and other exploratory efficacy measures in patients.

Keywords:

Caractéristiques de l'imagerie par résonance magnétique chez les patients atteints de spondylarthrite avec diagnostic clinique d'enthésite du talon : analyse post hoc de l'essai de phase 3 ACHILLES

Arthritis Res Ther. 2022 doi: 10.1186/s13075-022-02797-8

Behrens F; ACHILLES study group

Enthesitis is a hallmark feature of SpA, including PsA and axSpA, and is proposed as the primary lesion in spondyloarthropathies. This study aimed to investigate the imaging characteristics of heel enthesitis in SpA in a post hoc analysis using the HEMRIS in blinded and centrally read MRI data from the ACHILLES trial..